Back to search results

Observational Study on Microbiome in Cutaneous T Cell Lymphoma

This observational study aims to understand the community of microbes (microbiome) living on the skin of people with cutaneous T cell lymphoma (CTCL). Researchers will compare the skin microbiome of people with different stages of CTCL and those with CD30+ lymphoproliferative disorder (a group of conditions including lymphomatoid papulosis and cutaneous anaplastic large cell lymphoma) to people with plaque psoriasis. The study is open to adults aged 18 to 89. Success will be measured by looking at the diversity of bacteria on the skin after three months. The current recruitment status is unclear.

Study design
This is an observational study planning to enroll 300 participants. It aims to characterize the microbiome in different groups of patients.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint, bacterial diversity index, is measured at 3 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT03932279

Characterization of the Microbiome in Cutaneous T Cell Lymphoma

Recruiting
Not specifiedAges 18–89Observational
Northwestern University
~300 participants
Updated 2026-05-01 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Bacterial diversity index
Measured over 3 months

Conditions

Cutaneous T Cell Lymphoma

Explore related trials

Atopic DermatitisHealthyLymphoproliferative DisorderPrimary Cutaneous T-Cell Non-Hodgkin LymphomaPsoriasis

Where it's being run

1 sites across 1 states
Illinois1

Study leadership

  • Alan Zhou, MD · PRINCIPAL_INVESTIGATOR · Northwestern University

Who to contact

Dermatology CTU
[email protected]
312-503-5944
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Group 1: Patients with stage IA-IIA cutaneous T cell lymphoma
Group 2: Patients with stage IIB and above cutaneous T cell lymphoma
Group 3: Patients with CD30+ lymphoproliferative disorder including lymphomatoid papulosis and cutaneous anaplastic large cell lymphoma
Group 4: Patients with plaque psoriasis with BSA\>5% on routine phototherapy per standard of care
Group 5: Patients with moderate to severe atopic dermatitis on routine bleach bath therapy per standard of care
Group 6: Healthy individuals without the above skin conditions, similar age and sex distribution to the patients with cutaneous T cell lymphoma
All Groups: subjects who are age 18-89 years of age at time of enrollment
All Groups: Subjects who are able and willing to give informed consent for this study and the Dermatology Tissue Acquisition and Biorepository (STU00009443).

Exclusion

All Groups: Subjects who are younger than 18 years of age or older than 90 years of age
All Groups: Subjects who are unable to give consent
Patients currently on systemic antibiotics or recent (within past 4 weeks) exposure to systemic antibiotics
We will not recruit the following populations: adults unable to consent, individuals who are not yet adults (infants, children, teenagers), pregnant women, prisoners and other vulnerable populations.

What this trial measures

  • Bacterial diversity index3 months

    Diversity analysis of microbiome samples (measured by number of bacteria species/sample)